Belén Valenzuela

599 total citations
43 papers, 440 citations indexed

About

Belén Valenzuela is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Belén Valenzuela has authored 43 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 14 papers in Molecular Biology and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Belén Valenzuela's work include Cancer therapeutics and mechanisms (8 papers), Cancer Treatment and Pharmacology (7 papers) and Intraperitoneal and Appendiceal Malignancies (6 papers). Belén Valenzuela is often cited by papers focused on Cancer therapeutics and mechanisms (8 papers), Cancer Treatment and Pharmacology (7 papers) and Intraperitoneal and Appendiceal Malignancies (6 papers). Belén Valenzuela collaborates with scholars based in Spain, United States and Belgium. Belén Valenzuela's co-authors include Juan José Pérez Ruixo, Arturo Soto-Matos, A. Martín‐Villodre, Amparo Nácher, Emiliano Calvo, Ricardo Nalda‐Molina, José‐Esteban Peris, Gracia López‐Carballo, Domingo Barettino and Pedro Bretcha-Boix and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Neurology.

In The Last Decade

Belén Valenzuela

41 papers receiving 437 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Belén Valenzuela Spain 14 189 133 60 59 45 43 440
Xu Zhu China 16 220 1.2× 123 0.9× 80 1.3× 35 0.6× 72 1.6× 42 704
Shinji Kobuchi Japan 13 198 1.0× 122 0.9× 61 1.0× 53 0.9× 27 0.6× 61 529
J.H.M. Schellens Netherlands 10 378 2.0× 141 1.1× 28 0.5× 50 0.8× 19 0.4× 15 528
Muhammad Arshad Pakistan 8 90 0.5× 201 1.5× 33 0.6× 27 0.5× 26 0.6× 36 507
Mukul Minocha United States 13 256 1.4× 151 1.1× 18 0.3× 16 0.3× 120 2.7× 32 612
Victoria L. Elliott United Kingdom 5 83 0.4× 233 1.8× 82 1.4× 114 1.9× 62 1.4× 8 547
Robert G. Pietrusko United States 10 127 0.7× 209 1.6× 29 0.5× 35 0.6× 106 2.4× 15 607
M Slavík United States 12 127 0.7× 191 1.4× 36 0.6× 47 0.8× 25 0.6× 32 592
Omar Al‐Obeed Saudi Arabia 16 167 0.9× 259 1.9× 27 0.5× 75 1.3× 34 0.8× 36 622
Xiaomin Zhang China 15 409 2.2× 265 2.0× 129 2.1× 36 0.6× 151 3.4× 52 816

Countries citing papers authored by Belén Valenzuela

Since Specialization
Citations

This map shows the geographic impact of Belén Valenzuela's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Belén Valenzuela with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Belén Valenzuela more than expected).

Fields of papers citing papers by Belén Valenzuela

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Belén Valenzuela. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Belén Valenzuela. The network helps show where Belén Valenzuela may publish in the future.

Co-authorship network of co-authors of Belén Valenzuela

This figure shows the co-authorship network connecting the top 25 collaborators of Belén Valenzuela. A scholar is included among the top collaborators of Belén Valenzuela based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Belén Valenzuela. Belén Valenzuela is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Valenzuela, Belén, et al.. (2025). Evaluation of the Effect of Loperamide on the Cardiac Repolarization Interval Using Exposure–Response Analysis. Clinical and Translational Science. 18(2). e70114–e70114.
3.
Valenzuela, Belén, et al.. (2023). Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis. Clinical Pharmacokinetics. 62(11). 1533–1550. 6 indexed citations
4.
Valenzuela, Belén, et al.. (2022). Pharmacokinetic‐Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical Pharmacology & Therapeutics. 113(3). 692–703. 3 indexed citations
5.
Gars, Mathieu Le, Belén Valenzuela, Georgi Shukarev, et al.. (2022). Quantifying Antibody Persistence After a Single Dose of COVID‐19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach. Clinical Pharmacology & Therapeutics. 113(2). 380–389. 5 indexed citations
6.
Valenzuela, Belén, et al.. (2021). Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis. Clinical Pharmacokinetics. 60(9). 1239–1250. 6 indexed citations
7.
Olsson, Per, et al.. (2021). An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis. Clinical Pharmacokinetics. 60(9). 1227–1237. 5 indexed citations
8.
Poggesi, Italo, Belén Valenzuela, Danièle Ouellet, et al.. (2019). Population pharmacokinetics of trabectedin in adolescent patients with cancer. Cancer Chemotherapy and Pharmacology. 84(4). 707–717. 2 indexed citations
9.
Bretcha-Boix, Pedro, et al.. (2017). Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study. Clinical & Translational Oncology. 20(6). 785–793. 1 indexed citations
10.
Valenzuela, Belén, et al.. (2014). [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].. PubMed. 37(2). 111–27. 7 indexed citations
11.
Peris, José‐Esteban, et al.. (2014). Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients. Cancer Chemotherapy and Pharmacology. 73(5). 1009–1020. 7 indexed citations
12.
Ruixo, Juan José Pérez, et al.. (2014). Development and Validation of an HPLC-UV Method for Pazopanib Quantification in Human Plasma and Application to Patients With Cancer in Routine Clinical Practice. Therapeutic Drug Monitoring. 37(2). 172–179. 16 indexed citations
13.
Durán, Ignacio, et al.. (2013). Simultaneous online SPE–HPLC–MS/MS analysis of docetaxel, temsirolimus and sirolimus in whole blood and human plasma. Journal of Chromatography B. 921-922. 35–42. 34 indexed citations
14.
Valenzuela, Belén, et al.. (2013). Neutrophil Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin. Clinical Pharmacokinetics. 52(12). 1111–1125. 9 indexed citations
15.
Valenzuela, Belén, et al.. (2012). Population Pharmacokinetic–Pharmacodynamic Analysis of Neutropenia in Cancer Patients Receiving PM00104 (Zalypsis®). Clinical Pharmacokinetics. 51(11). 751–764. 10 indexed citations
16.
Ruixo, Juan José Pérez, et al.. (2012). Farmacocinética poblacional de cisplatino aplicada a la personalización de su dosificación en pacientes oncológicos. Farmacia Hospitalaria. 36(5). 392–402. 4 indexed citations
17.
Valenzuela, Belén, et al.. (2011). Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients. Cancer Chemotherapy and Pharmacology. 69(1). 15–24. 14 indexed citations
18.
Manzano, Ramón González, et al.. (2011). Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). Clinical & Translational Oncology. 13(11). 812–818. 7 indexed citations
19.
Valenzuela, Belén, et al.. (2006). Modelling intestinal absorption of salbutamol sulphate in rats. International Journal of Pharmaceutics. 314(1). 21–30. 4 indexed citations
20.
Valenzuela, Belén, et al.. (2001). The influence of active secretion processes on intestinal absorption of salbutamol in the rat. European Journal of Pharmaceutics and Biopharmaceutics. 52(1). 31–37. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xu Zhu Breakdown of academic impact, for papers by Shinji Kobuchi Breakdown of academic impact, for papers by J.H.M. Schellens Breakdown of academic impact, for papers by Muhammad Arshad Breakdown of academic impact, for papers by Mukul Minocha Breakdown of academic impact, for papers by Victoria L. Elliott Breakdown of academic impact, for papers by Robert G. Pietrusko Breakdown of academic impact, for papers by M Slavík Breakdown of academic impact, for papers by Omar Al‐Obeed Breakdown of academic impact, for papers by Xiaomin Zhang
Rankless by CCL
2026